Concepedia

Author

Kenichi Fukumoto

Taisho Pharmaceutical (Japan)

Also Known As

K Fukumoto, Ken-ichi Fukumoto, Kenichi Fukumoto

26

Publications

1.4K

Citations

17

H-Index

34

Concepts

All Affiliations

Taisho Pharmaceutical (Japan)Yale UniversitySumitomo Dainippon Pharma (Japan)
KF

About

Kenichi Fukumoto is an author at Taisho Pharmaceutical (Japan) specializing in neuropharmacology, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

671

2

Social Sciences

8

8

627

3

Neuroscience

8

8

627

4

Neurology

1

1

29

5

Nutrition

1

1

64

Kenichi Fukumoto

×

14

Publications

1.3K

Citations

14

H-Index

YearCitations

Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine

Kenichi Fukumoto, Hidetoh Toki, Michihiko Iijima,

Journal of Pharmacology and Experimental Therapeutics

2017

245

Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine

Kenichi Fukumoto, Manoela V. Fogaça, Rong-Jian Liu,

Proceedings of the National Academy of Sciences

2018

180

The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN

Kenichi Fukumoto, Michihiko Iijima, Shigeyuki Chaki

Neuropsychopharmacology

2015

169

Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test

Kenichi Fukumoto, Michihiko Iijima, Shigeyuki Chaki

Psychopharmacology

2014

101

Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression

Hiroyuki Koike, Kenichi Fukumoto, Michihiko Iijima,

Behavioural Brain Research

2012

93

BDNF release and signaling are required for the antidepressant actions of GLYX-13

T. KATO, Manoela V. Fogaça, Satoshi Deyama,

Molecular Psychiatry

2017

90

Role of 5-HT1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine

Kenichi Fukumoto, Michihiko Iijima, Takeo Funakoshi,

The International Journal of Neuropsychopharmacology

2017

83

N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects

Manoela V. Fogaça, Kenichi Fukumoto, Tina Franklin,

Neuropsychopharmacology

2019

79

Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test

Michihiko Iijima, Kenichi Fukumoto, Shigeyuki Chaki

Behavioural Brain Research

2012

64

Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin <scp>V<sub>1B</sub></scp> receptor antagonists: <scp>TASP</scp>0233278 and <scp>TASP</scp>0390325

Michihiko Iijima, Takao Yoshimizu, Takunori Shimazaki,

British Journal of Pharmacology

2014

53

Page 1